The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:

To the Editor: Dr. Dewan demonstrated by simple addition that one more than one equals two: that health plan fees for combined psychotherapy and pharmacotherapy by a psychiatrist cost less than split treatment by a pharmacologist and a nonpsychiatrist psychotherapist. This elegant and clever brief report deserves acclaim, given the paucity of research on this topic. Psychiatry must broaden its literature to ensure its economic survival (1). The American Psychiatric Association’s Commission on Psychotherapy by Psychiatrists seconds Dr. Dewan’s call for the clinical trials that are now desperately needed to supplement his accounting. This research should assess not simply cost (cf. Goldman et al., 1998) but also the quality and associated outcomes of treatment: remission of patient symptoms, restored or enhanced function, and better quality of life.

References

1. Markowitz JC: Managed care and American psychotherapy, in Manage or Perish: The Challenges of Managed Mental Health Care in Europe. Edited by Guimon G, Sartorius N. New York, Plenum Publishing, 1999Google Scholar